Chugai Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical products in the areas of oncology, renal diseases, bone and joint diseases, and other diseases in Japan and internationally. The company is also conducting research and development activities in diabetes area and infectious diseases area. Products ONCOLOGY FIELD Neutrogin: Neutrogin is a recombinant human granulocytecolony stimulating factor (G-CSF) developed by the company. G-CSF is a hematopoietic factor that specifically promotes the differentiation and growth of cells of the granulocytic series (especially neutrophils) in bone marrow. Neutrogin is used to treat neutropenia that occurs as a side effect of anti-cancer agents, mobilize peripheral blood progenitor cells, promote neutrophilia after hematopoietic cell transplantation, and treat neutropenia associated with myelodysplastic syndrome, aplastic anemia, HIV infection, and immunosuppressive therapy following kidney transplantation. Overseas, Neutrogin is sold under the name Granocyte. Herceptin: Herceptin is a targeted monoclonal antibody that works across various stages of human epidermal growth factor receptor type 2 (HER2)-positive breast cancer. The product specifically activates the immune system and suppresses the HER2 protein that contributes to tumor cell growth. In Japan, the product is indicated for the treatment of patients with metastatic breast cancer with HER2 over-expression and also for postoperative adjuvant therapy of patients with early HER2-positive breast cancer. Rituxan: Rituxan is a targeted monoclonal antibody for the treatment of CD20-positive, B-cell non- Hodgkin’s lymphoma. It works by binding to a specific protein (the CD20 antigen) found on the surface of normal and malignant B cells, activating the immune system to eliminate the marked cells. These are then replaced by healthy B cells from the bone marrow. In Japan, Rituxan is marketed jointly by Chugai and Zenyaku Kogyo Co., Ltd. Outside Japan and North America, Rituxan is sold under the brand-name MabThera by the Roche Group. Avastin: The humanized anti-VEGF (vascular endothelial growth factor) monoclonal antibody Avastin is an anti-angiogenesis agent. Avastin inhibits angiogenesis — the growth of the network of blood vessels that supply nutrients and oxygen to cancerous tissues. Avastin is marketed globally by Roche Group companies. In Japan, Avastin is approved for the treatment of advanced and recurrent colorectal cancer. Kytril: Kytril is a selective inhibitor of the 5-HT3 (serotonin) receptors found in afferent vagal nerve endings distributed mainly along the gastrointestinal tract. It is prescribed as an antiemetic agent to alleviate nausea and vomiting caused by the adverse reactions due to anticancer agents. Xeloda: Xeloda is a drug with high target specificity. Xeloda is the treatment for metastatic breast cancer and colorectal cancer. In Japan, Xeloda is used to treat inoperable or recurrent breast cancer and as a postoperative adjuvant chemotherapy for colon cancer. Tarceva: Tarceva is a targeted, small-molecule drug that inhibits the activation of human epidermal growth factor receptor (EGFR) by blocking the enzyme tyrosine kinase. EGFR plays a key role in the growth, progression, and metastasis of cancer. The product is marketed overseas by Roche, Genentech, and OSI Pharmaceuticals. It is approved in Europe and the United States for the second-line treatment of advanced nonsmall cell lung cancer and the first-line treatment of metastatic pancreatic cancer. In Japan, Tarceva is approved for the second-line or later treatment of non-small cell lung cancer. Femara: The company has commenced joint marketing of Femara, an aromatase inhibitor, with Novartis Pharma K.K., Femara’s manufacturer and distributor. Femara is a drug used in endocrine therapies for breast cancer and it has been approved in approximately 100 countries worldwide as a breast cancer treatment for postmenopausal women. TP300: TP300 is a topoisomerase I inhibitor which prevents the growth of cancer cells by obstructing the activity of an enzyme called topoisomerase I, which contributes to t
chugai pharmaceutical co ltd
Nihonbashi Mitsui Tower
1-1 Nihonbashi-Muromachi 2-Chome
Phone: 81 3 3281 6611
Fax: 81 3 3281 6607www.chugai-pharm.co.jp
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for CUP.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact CHUGAI PHARMACEUTICAL CO LTD, please visit www.chugai-pharm.co.jp. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.